Drugs / CP-724,714
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00055926 | Jan 2003 → Dec 2004 | breast cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00102895 | Apr → Sep 2005 | breast cancer, metastatic malignant neoplasm | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-724,714 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00055926 ↗ |
| Action | Inhibit | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL483321 ↗ |
| Modality | Small molecule | — CHEMBL483321 ↗ |
| Route | Oral | “Patients receive oral CP-724,714” NCT00055926 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL483321 ↗ |